Company: CRNX
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057452
Chunk: 49

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 49
---
 group to determine whether additional or different peer companies or groups are necessary to provide appropriate information on market practices and compensation levels for 2024; and 
 •Provides general information concerning director and executive compensation trends and developments during 2024.                                                                                        |
| Pearl Meyer | •Facilitates a review of our compensation philosophy with our compensation committee and chief executive officer;                                                                                        
 •Conducts a review of our peer group which used to inform competitive compensation levels and practices at companies similar to ours;                                                                    |

<div align='center'>34</div>

| •Evaluates the compensation of our named executive officers versus market benchmarks;                       
 •Reviews and makes design recommendations with respect to our short- and long-term incentive plan for 2025; 
 •Evaluates non-employee director compensation versus market benchmarks;                                     
 •Conducts an annual compensation program risk assessment;                                                   
 •Performs other ad hoc requests related to executive and/or director compensation starting in August 2024.  |

Aon and Pearl Meyer did not provide any other services to us in 2024 beyond their engagements as advisors to the compensation committee on director and executive compensation matters. The compensation committee assessed the independence of Aon and Pearl Meyer pursuant to SEC and Nasdaq rules and concluded that no conflict of interest existed that would have prevented Aon and Pearl Meyer from serving as an independent consultant to the compensation committee currently or during 2024. Competitive Positioning Our compensation committee strives to set a competitive level of total compensation for each NEO as compared with executive officers in similar positions at peer companies. The compensation committee regularly reviews the company’s peer group to ensure it reflects organizations that are most relevant for benchmarking executive compensation. For the purposes of setting 2024 compensation levels, the compensation committee conducted an in-depth assessment of potential comparators to evaluate the degree to which the current peer companies are aligned with our company’s growth and evolution. New companies were added to the peer group to maintain relevance and ensure alignment with our size, industry, and competitive landscape, while several companies were removed due to acquisition or significant changes in their business status or market capitalization:

| Additions              | Removals                |
| Akero Therapeutics     | AnaptysBio              |
| Cerevel Therapeutics   | Arcturus Therapeutics   |
| Cytokinetics           | Gossamer Bio            |
| IDEAYA Biosciences     | Kezar Life Sciences     |
| ImmunoGen              | Lexicon Pharmaceuticals |
| Immunovant             | M